Versant Capital Management’s Arcus Biosciences RCUS Stock Holding History

Versant Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.25K	Hold	358	–	–	﹤0.01%	2288
2026 Q2	$11K	Hold	358	–	–	﹤0.01%	2201
2026 Q1	$7.73K	Hold	358	–	–	﹤0.01%	2242
2025 Q4	$8.53K	Hold	358	–	–	﹤0.01%	2068
2025 Q3	$4.87K	Hold	358	–	–	﹤0.01%	2216
2025 Q2	$2.91K	Sell	358 -415	-54%	-$3.54K	﹤0.01%	2310
2025 Q1	$6.07K	Buy	773 +525	+212%	+$6.09K	﹤0.01%	1960
2024 Q4	$3.69K	Buy	248 +9	+4%	+$147	﹤0.01%	1900
2024 Q3	$3.65K	Buy	239 +100	+72%	+$1.58K	﹤0.01%	1384
2024 Q2	$2.12K	Buy	+139	New	+$2.24K	﹤0.01%	1494
2023 Q1	–	Sell	-10	Closed	-$207	–	1799
2022 Q4	$207	Sell	10 -2	-17%	-$55	﹤0.01%	1597
2022 Q3	$0	Sell	12 -1	-8%	-$26	﹤0.01%	1608
2022 Q2	$0	Hold	13	–	–	﹤0.01%	1608
2022 Q1	$0	Hold	13	–	–	﹤0.01%	1593
2021 Q4	$1K	Hold	13	–	–	﹤0.01%	1330
2021 Q3	$0	Hold	13	–	–	﹤0.01%	1564
2021 Q2	$0	Hold	13	–	–	﹤0.01%	1572
2021 Q1	$0	Hold	13	–	–	﹤0.01%	1588
2020 Q4	$0	Buy	+13	New	+$315	﹤0.01%	1497

Other funds holding RCUS

Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Versant Capital Management's RCUS Position: Q3 2026 in Review

Versant Capital Management held its Arcus Biosciences (RCUS) position steady in Q3 2026 at 358 shares worth $9.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

Versant Capital Management first reported a position in RCUS in Q4 2020 and has held it in 19 quarters since. The position peaked at $11K in Q2 2026. 85 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

Versant Capital Management held 358 shares of Arcus Biosciences worth $9.25K as of Q3 2026.
Versant Capital Management left its Arcus Biosciences share count unchanged in Q3 2026.
Arcus Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2288 holding.
Versant Capital Management first reported a position in Arcus Biosciences in Q4 2020 and has held it in 19 quarters since.
Versant Capital Management's Arcus Biosciences position peaked at $11K in Q2 2026.
85 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.